Surgical management and prognostic factors for primary intracranial myxoma: a single-institute experience with a systematic review

Restricted access

OBJECTIVE

Primary intracranial myxomas (PICMs) are extremely rare neoplasms, and their management and prognostic factors remain ambiguous. The authors aimed to elaborate the radiological features, evaluate the risk factors for progression-free survival (PFS), and propose a treatment protocol based on pooled data from cases treated at their institute and those found in the literature.

METHODS

Clinical data from all cases of PICMs treated at the authors’ institute and those cases reported in the English-language literature between 1987 and December 2017 were reviewed. The authors searched the Ovid MEDLINE, Embase, PubMed, and Cochrane databases using the keywords “myxoma” and “central nervous system,” “intracranial,” “cerebral,” “skull base,” “skull,” or “brain.” Previously published data were processed and used according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Risk factors in the pooled cohort were evaluated.

RESULTS

Cases from the authors’ institute included 21 males and 9 females, with a mean age of 35.7 ± 1.7 years. Gross-total resection (GTR) and non-GTR were achieved in 6 (20.0%) and 24 (80.0%) patients, respectively. After a mean follow-up of 86.7 ± 14.1 months, recurrence occurred in 6 (24%) patients, for a median PFS time of 85.2 months (range 36.0–136.0 months) and no deaths. In the literature between 1987 and 2017, 35 cases of PICM were identified in 14 males and 21 females with a mean age of 31.7 ± 3.2 years. GTR and non-GTR were achieved in 23 (65.7%) and 9 (25.7%) cases, respectively. After a mean follow-up of 25.8 ± 6.9 months (range 1.0–156.0 months), recurrence occurred in 4 (14.3%) patients, for a median PFS time of 11.0 months (range 3.0–36.0 months) and no deaths. Actuarial PFS rates at 1, 5, and 10 years were 93.0%, 80.6%, and 67.9%, respectively. A multivariate model demonstrated that GTR (HR 0.058, 95% CI 0.005–0.680, p = 0.023) was the only factor that favored PFS.

CONCLUSIONS

PICMs are rare neoplasms with a slightly higher occurrence in males. GTR was the only favorable factor for PFS. Based on statistical results, GTR alone, if tolerable, is advocated as the optimal treatment for PICM. Nevertheless, conservative excision may be preferred to avoid damage to vital structures. PICMs have a tendency to recur within a few years of the initial surgery if resection is incomplete; therefore, close postoperative follow-up is mandatory. Future studies with larger cohorts are necessary to verify the study findings.

Systematic review registration no.: CRD42018091517 (www.crd.york.ac.uk/prospero/)

ABBREVIATIONS BTH = Beijing Tiantan Hospital; CN = cranial nerve; CNS = central nervous system; EMA = epithelial membrane antigen; EMPT = estimated mean PFS time; GFAP = glial fibrillary acidic protein; GKS = Gamma Knife surgery; GTR = gross-total resection; IMRT = intensity-modulated RT; PFS = progression-free survival; PICM = primary intracranial myxoma; RT = radiotherapy.

Supplementary Materials

  • Supplementary Table 1 (PDF 378 KB)
Article Information

Contributor Notes

Correspondence Jun-Ting Zhang: Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China. zhangjunting2003@aliyun.com.INCLUDE WHEN CITING Published online November 30, 2018; DOI: 10.3171/2018.6.JNS181132.

J.C.W., L.R.S., and D.L. contributed equally to this work.

Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

© AANS, except where prohibited by US copyright law.

Headings
TrendMD
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 98 98 98
Full Text Views 182 182 182
PDF Downloads 33 33 33
EPUB Downloads 0 0 0
PubMed
Google Scholar